273 related articles for article (PubMed ID: 21685905)
1. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.
Addona TA; Shi X; Keshishian H; Mani DR; Burgess M; Gillette MA; Clauser KR; Shen D; Lewis GD; Farrell LA; Fifer MA; Sabatine MS; Gerszten RE; Carr SA
Nat Biotechnol; 2011 Jun; 29(7):635-43. PubMed ID: 21685905
[TBL] [Abstract][Full Text] [Related]
2. Streamlining biomarker discovery.
Latterich M; Schnitzer JE
Nat Biotechnol; 2011 Jul; 29(7):600-2. PubMed ID: 21747385
[No Abstract] [Full Text] [Related]
3. A targeted proteomics-based pipeline for verification of biomarkers in plasma.
Whiteaker JR; Lin C; Kennedy J; Hou L; Trute M; Sokal I; Yan P; Schoenherr RM; Zhao L; Voytovich UJ; Kelly-Spratt KS; Krasnoselsky A; Gafken PR; Hogan JM; Jones LA; Wang P; Amon L; Chodosh LA; Nelson PS; McIntosh MW; Kemp CJ; Paulovich AG
Nat Biotechnol; 2011 Jun; 29(7):625-34. PubMed ID: 21685906
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.
Ngo D; Sinha S; Shen D; Kuhn EW; Keyes MJ; Shi X; Benson MD; O'Sullivan JF; Keshishian H; Farrell LA; Fifer MA; Vasan RS; Sabatine MS; Larson MG; Carr SA; Wang TJ; Gerszten RE
Circulation; 2016 Jul; 134(4):270-85. PubMed ID: 27444932
[TBL] [Abstract][Full Text] [Related]
5. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.
Addona TA; Abbatiello SE; Schilling B; Skates SJ; Mani DR; Bunk DM; Spiegelman CH; Zimmerman LJ; Ham AJ; Keshishian H; Hall SC; Allen S; Blackman RK; Borchers CH; Buck C; Cardasis HL; Cusack MP; Dodder NG; Gibson BW; Held JM; Hiltke T; Jackson A; Johansen EB; Kinsinger CR; Li J; Mesri M; Neubert TA; Niles RK; Pulsipher TC; Ransohoff D; Rodriguez H; Rudnick PA; Smith D; Tabb DL; Tegeler TJ; Variyath AM; Vega-Montoto LJ; Wahlander A; Waldemarson S; Wang M; Whiteaker JR; Zhao L; Anderson NL; Fisher SJ; Liebler DC; Paulovich AG; Regnier FE; Tempst P; Carr SA
Nat Biotechnol; 2009 Jul; 27(7):633-41. PubMed ID: 19561596
[TBL] [Abstract][Full Text] [Related]
6. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
Jacob J; Ngo D; Finkel N; Pitts R; Gleim S; Benson MD; Keyes MJ; Farrell LA; Morgan T; Jennings LL; Gerszten RE
Circulation; 2018 Mar; 137(12):1270-1277. PubMed ID: 29222138
[TBL] [Abstract][Full Text] [Related]
7. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.
Rifai N; Gillette MA; Carr SA
Nat Biotechnol; 2006 Aug; 24(8):971-83. PubMed ID: 16900146
[TBL] [Abstract][Full Text] [Related]
8. A new data mining approach for profiling and categorizing kinetic patterns of metabolic biomarkers after myocardial injury.
Baumgartner C; Lewis GD; Netzer M; Pfeifer B; Gerszten RE
Bioinformatics; 2010 Jul; 26(14):1745-51. PubMed ID: 20483816
[TBL] [Abstract][Full Text] [Related]
9. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Smith JG; Gerszten RE
Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
[TBL] [Abstract][Full Text] [Related]
10. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.
Keshishian H; Addona T; Burgess M; Mani DR; Shi X; Kuhn E; Sabatine MS; Gerszten RE; Carr SA
Mol Cell Proteomics; 2009 Oct; 8(10):2339-49. PubMed ID: 19596694
[TBL] [Abstract][Full Text] [Related]
11. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.
Lewis GD; Wei R; Liu E; Yang E; Shi X; Martinovic M; Farrell L; Asnani A; Cyrille M; Ramanathan A; Shaham O; Berriz G; Lowry PA; Palacios IF; Taşan M; Roth FP; Min J; Baumgartner C; Keshishian H; Addona T; Mootha VK; Rosenzweig A; Carr SA; Fifer MA; Sabatine MS; Gerszten RE
J Clin Invest; 2008 Oct; 118(10):3503-12. PubMed ID: 18769631
[TBL] [Abstract][Full Text] [Related]
12. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.
Chambers AG; Percy AJ; Simon R; Borchers CH
Expert Rev Proteomics; 2014 Apr; 11(2):137-48. PubMed ID: 24476379
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.
Keshishian H; Burgess MW; Gillette MA; Mertins P; Clauser KR; Mani DR; Kuhn EW; Farrell LA; Gerszten RE; Carr SA
Mol Cell Proteomics; 2015 Sep; 14(9):2375-93. PubMed ID: 25724909
[TBL] [Abstract][Full Text] [Related]
14. Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach.
Cheow ESH; Cheng WC; Yap T; Dutta B; Lee CN; Kleijn DPV; Sorokin V; Sze SK
J Proteome Res; 2018 Jan; 17(1):499-515. PubMed ID: 29068691
[TBL] [Abstract][Full Text] [Related]
15. Qualification and Verification of Protein Biomarker Candidates.
Zhao Y; Brasier AR
Adv Exp Med Biol; 2016; 919():493-514. PubMed ID: 27975232
[TBL] [Abstract][Full Text] [Related]
16. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
17. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
18. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative.
Yin X; Subramanian S; Hwang SJ; O'Donnell CJ; Fox CS; Courchesne P; Muntendam P; Gordon N; Adourian A; Juhasz P; Larson MG; Levy D
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):939-45. PubMed ID: 24526693
[TBL] [Abstract][Full Text] [Related]
19. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification.
Makawita S; Diamandis EP
Clin Chem; 2010 Feb; 56(2):212-22. PubMed ID: 20007861
[TBL] [Abstract][Full Text] [Related]
20. Proteomic Discovery and Validation of the Confounding Effect of Heparin Administration on the Analysis of Candidate Cardiovascular Biomarkers.
Beck HC; Jensen LO; Gils C; Ilondo AMM; Frydland M; Hassager C; Møller-Helgestad OK; Møller JE; Rasmussen LM
Clin Chem; 2018 Oct; 64(10):1474-1484. PubMed ID: 30115630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
